# A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

> **NCT05601128** · PHASE3 · COMPLETED · sponsor: **Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)** · enrollment: 12 (actual)

## Conditions studied

- HIV-1-infection
- HIV Infections
- HIV I Infection

## Interventions

- **DRUG:** CAB + RPV

## Key facts

- **NCT ID:** NCT05601128
- **Lead sponsor:** Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601128, "A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05601128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*